410 related articles for article (PubMed ID: 12790774)
21. Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer.
Osborne CK
Endocr Relat Cancer; 1999 Jun; 6(2):271-6. PubMed ID: 10731120
[TBL] [Abstract][Full Text] [Related]
22. Anti-tumor effects of letrozole.
Miller WR; Anderson TJ; Dixon JM
Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
[TBL] [Abstract][Full Text] [Related]
23. Future use of selective estrogen receptor modulators and aromatase inhibitors.
Howell A
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4402s-4410s; discussion 4411s-4412s. PubMed ID: 11916232
[TBL] [Abstract][Full Text] [Related]
24. Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation.
Song RX; McPherson RA; Adam L; Bao Y; Shupnik M; Kumar R; Santen RJ
Mol Endocrinol; 2002 Jan; 16(1):116-27. PubMed ID: 11773443
[TBL] [Abstract][Full Text] [Related]
25. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
Lewis JS; Jordan VC
Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919
[TBL] [Abstract][Full Text] [Related]
26. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
Johnston SR
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
[TBL] [Abstract][Full Text] [Related]
27. Aromatase inhibitors: rationale for use following antiestrogen therapy.
Yue W; Santen RJ
Semin Oncol; 1996 Aug; 23(4 Suppl 9):21-7. PubMed ID: 8824461
[TBL] [Abstract][Full Text] [Related]
28. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
Jordan VC; Brodie AM
Steroids; 2007 Jan; 72(1):7-25. PubMed ID: 17169390
[TBL] [Abstract][Full Text] [Related]
29. Estrogen metabolites and breast cancer.
Santen RJ; Yue W; Wang JP
Steroids; 2015 Jul; 99(Pt A):61-6. PubMed ID: 25168343
[TBL] [Abstract][Full Text] [Related]
30. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
McDaniel RE; Maximov PY; Jordan VC
Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
[TBL] [Abstract][Full Text] [Related]
31. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936
[TBL] [Abstract][Full Text] [Related]
32. Prevention of breast cancer using SERMs and aromatase inhibitors.
Strassmer-Weippl K; Goss PE
J Mammary Gland Biol Neoplasia; 2003 Jan; 8(1):5-18. PubMed ID: 14587860
[TBL] [Abstract][Full Text] [Related]
33. Molecularly targeted endocrine therapies for breast cancer.
Orlando L; Schiavone P; Fedele P; Calvani N; Nacci A; Rizzo P; Marino A; D'Amico M; Sponziello F; Mazzoni E; Cinefra M; Fazio N; Maiello E; Silvestris N; Colucci G; Cinieri S
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S67-71. PubMed ID: 21129614
[TBL] [Abstract][Full Text] [Related]
34. Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators?
Lupu R; Menendez JA
Endocrinology; 2006 Sep; 147(9):4056-66. PubMed ID: 16809439
[TBL] [Abstract][Full Text] [Related]
35. New approaches to the understanding of tamoxifen action and resistance.
Berstein LM; Zheng H; Yue W; Wang JP; Lykkesfeldt AE; Naftolin F; Harada H; Shanabrough M; Santen RJ
Endocr Relat Cancer; 2003 Jun; 10(2):267-77. PubMed ID: 12790788
[TBL] [Abstract][Full Text] [Related]
36. 2',3',4'-Trihydroxychalcone changes estrogen receptor α regulation of genes and breast cancer cell proliferation by a reprogramming mechanism.
Herber CB; Yuan C; Chang A; Wang JC; Cohen I; Leitman DC
Mol Med; 2022 Apr; 28(1):44. PubMed ID: 35468719
[TBL] [Abstract][Full Text] [Related]
37. The potential for aromatase inhibition in breast cancer prevention.
Lønning PE; Kragh LE; Erikstein B; Hagen A; Risberg T; Schlichting E; Geisler J
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4423s-4428s; discussion 4411s-4412s. PubMed ID: 11916235
[TBL] [Abstract][Full Text] [Related]
38. Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol.
Yue W; Wang JP; Conaway M; Masamura S; Li Y; Santen RJ
Endocrinology; 2002 Sep; 143(9):3221-9. PubMed ID: 12193533
[TBL] [Abstract][Full Text] [Related]
39. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
[TBL] [Abstract][Full Text] [Related]
40. Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells.
Jeng MH; Yue W; Eischeid A; Wang JP; Santen RJ
Breast Cancer Res Treat; 2000 Aug; 62(3):167-75. PubMed ID: 11072781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
